Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.
about
HSV-2: in pursuit of a vaccineIncidence of herpes simplex virus type 2 infections in Africa: a systematic reviewFactors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study.Current status and prospects for development of an HSV vaccineContribution of sexually transmitted infections to the sexual transmission of HIV.The Interplay between Sexually Transmitted Infections and HIV: An Evolving StoryA single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.Individual-based simulation models of HIV transmission: reporting quality and recommendations.The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.SR-2P vaginal microbicide gel provides protection against herpes simplex virus 2 when administered as a combined prophylactic and postexposure therapeuticHerpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and preventionEffect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007.Modelling the interactions between herpes simplex virus type 2 and HIV: implications for the HIV epidemic in southern India.Future prospects for new vaccines against sexually transmitted infections.Biological basis for the protective effect conferred by male circumcision against HIV infection.A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Sexually Transmitted Bedfellows: Exquisite Association between HIV and HSV2 in 21 Communities in Southern Africa in the HPTN 071 (PopART) Study.
P2860
Q22306291-5161C8C5-DDC8-4BAC-95EB-EF75BF794F4AQ27690876-AE057FB5-CE9A-494F-B946-99EC34645752Q33851349-CF1B3470-7FAA-4C97-989C-BEF7C9B52885Q33931016-156B0792-E0CF-401D-B050-F2E34CAA19B7Q34071194-DA84598E-1452-4911-B393-470E76E3EB90Q34196145-E17EFF4D-AD0D-4EAD-AE2D-009823704B2AQ34414463-52AFD7DD-025A-4813-BCD7-22A4008DF84EQ34549656-E5DCD4E3-945F-4215-AE40-95777A8E0FF3Q35010032-5536F9EA-C337-4F33-ADE2-B453FD7CD1C7Q35169355-FADFFF83-890E-4170-AF02-874338C9915DQ35960877-6F50FCE6-6694-464D-9133-66C9F6A92ABCQ36824210-4B606A04-FBE9-416C-9F34-49A7870C49B3Q37164885-3FBD6C2C-D7D3-4038-BE45-EEDD852AE470Q37455685-F00CB74D-4B49-4FE7-8C26-23657D44A402Q37575589-2FD1D3F5-BCD5-4CF9-B293-57560E5FA778Q37665012-C86357E4-5703-4E1B-AEDE-3FE78223E957Q38009780-661CB7E1-BBEB-4BF2-B3B7-C3113246726BQ40210971-143EFADA-EA73-48A3-8349-C8DE43A97605Q41928445-BE0DC25C-8E72-4348-B090-A7F7517811C0Q53409715-7FCC0456-963E-46FA-AE4E-29A8070936EC
P2860
Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@en
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@nl
type
label
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@en
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@nl
prefLabel
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@en
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@nl
P2093
P2860
P1433
P1476
Population-level effect of pot ...... cidence in sub-Saharan Africa.
@en
P2093
Esther E Freeman
Helen A Weiss
Judith R Glynn
Kate K Orroth
Roel Bakker
P2860
P304
P356
10.1016/J.VACCINE.2008.11.074
P407
P577
2008-12-09T00:00:00Z